Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK8 | O60259 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | PLG | P00747 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | KLK4 | Q9Y5K2 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | KLK1 | P06870 | 2/20 | 0.43 |
| ▸ | KLK2 | P20151 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353765 | 0.91 | PPARG (0.48) | PPARGBACE1 | |
| SCHEMBL2352431 | 0.89 | ELANE (0.47) | PPARGBACE1 | |
| SCHEMBL2357307 | 0.87 | ACE2 (0.51) | PPARG | |
| SCHEMBL2354254 | 0.85 | MGLL (0.43) | PPARGBACE1MGLL | |
| SCHEMBL2353069 | 0.85 | PPARG (0.41) | KLK8F10PLGPLAUKLK4 | |
| SCHEMBL2354791 | 0.85 | SIRT2 (0.45) | KLK8PLGPLAUKLK4F2 | |
| SCHEMBL2350511 | 0.83 | GRB2 (0.45) | F2BACE1 | |
| SCHEMBL2350530 | 0.83 | PPARG (0.43) | PPARG | |
| SCHEMBL2353492 | 0.82 | PPARG (0.42) | PPARG | |
| SCHEMBL2353485 | 0.82 | MMP3 (0.44) | PPARGBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | claimed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | claimed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | claimed |
| EP-1874322-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-09 | — | — | EP | claimed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | claimed |
| WO-2006113247-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-26 | — | — | WO | claimed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | claimed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | claimed |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | disclosed |
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | disclosed |
| EP-1874322-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1817041-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | disclosed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
| WO-2006113247-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-26 | — | — | WO | disclosed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | disclosed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | disclosed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SERPINB1, TFPI, TFPI2 | KLK8 1089/4885F10 189/4885PLG 58/4885 |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | CPB1, CPB2, CPA1 | KLK8 903/4885F10 171/4885PLG 35/4885 |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | CPB1, CPB2, CPA1 | KLK8 903/4885F10 171/4885PLG 35/4885 |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | TFPI, TFPI2, TNNI3 | KLK8 1370/4885F10 233/4885PLG 32/4885 |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | CPB1, CPB2, CPA1 | KLK8 1030/4885F10 167/4885PLG 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.